Nanome Agents co-folded top candidates after every REINVENT4 cycle
Public source
Publisher name
Public post
One of our favorite checks in the pipeline: Nanome Agents compared Boltz2, Protenix, and OpenFold3 predictions against the experimental crystal structure. Then co-folded…
Company
Nanome
Scaling Humanity
- Industry
- Software Development
- Location
- San Diego, US
- Company size
- 11–50 employees
About Nanome
Nanome is the ultimate interface for scientific discovery, starting with molecular data. Top R&D labs conduct cutting-edge research and make billion-dollar decisions in Nanome. But, Nanome isn’t just for experts, it’s also used by students and amateur scientists studying chemistry and biology. Anyone can build 3D molecules or simulate an entire protein made of hundreds of atoms, all in one collaborative environment. Transform the way you learn, design, and communicate molecular structures with Nanome. Available on the new Meta Quest Pro.
See moreLatest activity
Latest activity from Nanome
4 signals
Presence & Recognition
Nanome is hosting a live webinar featuring Nanome Agents
Research & Knowledge
Nanome Agents compared Boltz2, Protenix, and OpenFold3 predictions against the experimental crystal structure
Presence & Recognition
Nanome is hosting a webinar on September 3rd to share more about Nanome Agents
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
QSimulate
QSimulate published the OpenBind Consortium dropping a co-folding model with 717 hard new structures and a clear list of where it fails.
Research & Knowledge
RECEPTOR.AI
RECEPTOR.AI is finalizing an upcoming whitepaper featuring internal benchmark results demonstrating the capabilities of ForceFold, a co-folding architecture conditioned by physics-based methods.
Research & Knowledge
Clutch Holdings
Clutch Holdings reported that a team screened roughly thirty thousand compounds against protein structures predicted by AlphaFold found two existing drugs, pimecrolimus and ledipasvir, active against the parasite in the lab.
Research & Knowledge
Pharmacelera
Pharmacelera delivered the CACHE Challenge #5 benchmark, where 24 teams worldwide competed to find novel antagonists of MCHR1 using a shared dataset of 2,605 ChEMBL compounds and 753 patented molecules.
Research & Knowledge
Neoncorte Bio